Wolfgang Dean XXXX Officer; Thank of Research; you, Commercial President joining Also, call. CFO. me Masuda, Schorno, year-end our our Dolly our our our today Officer; and Chief Esteban and thank Dave Vice quarter you on for Chief joining and fourth Executive are Santos, Medical us Dummer,
X. Slide on Now, starting
accomplish the what Rigel, and we coming bit year me Let look have we about beyond. little accomplished a and tell and in to you
you as we value of and turn, challenging progress industry, other emerged. was all drivers will good across opportunities you tell an key difficult had we we these those. most the although about will each four in – drivers. tell and XXXX challenging to continue very also Rigel, of we’ve have make We year, perhaps a at And
our the chronic ITP. not grow In Our our mostly treatment first continue our of priority TAVALISSE and is did sales the growth. organization in basis. field our virtual to to a use This we interactions product stop early pulled XXXX, from the moved to of
this grew this Our very XX% Starting we much we back over to better continuing pandemic. doubt in team XXXX, XXXX, backdrop $XX.X a field, to the been focused the product. on to early-line have the supporting would educating XXXX. and of that have in and forward increase look year, going in I sales later result million a into of And is given good the we we XXXX. in This no field our had use done on
we in of Canada. U.S., We minute. will this bit made in a XXXX. more tell Outside approvals about received both very in the good We progress a you Europe and
launched indication outside more The $X ITP progress make Grifols product continue is million a partner, $X.X XXXX, very XXXX. U.S., of and market. the basis global billion and a are the in is UK in tremendous on our about market, for XXXX. country a billion Our opportunity launches planned attractive Germany in in this of $XXX and we to to hemolytic the autoimmune growing companion here, And U.S. a anemia. warm ITP and
and be goal the be out market. our warm the product hemolytic first approved being targeted. And pandemic most we development we for built-in The enrollment; the anemia. the of fact, the continue treatment here However, on to is first of already the of with in to clinical autoimmune advanced advantage in product on be to having impact XX the XX second wave the of an enrolled have is patients
aim including And a to it, market A program. We is preclinically share second. COVID-XX, COVID-XX a Imperial the our the Phase have a a of market. NIH Phase and a billion more our London tell and at comprehensive for College by use. COVID in also first – did of XXX in numerous opportunity study and patients. fostamatinib year hospitalized launched into gain Harvard, exciting. that hospitalized tremendous the treating colleagues study $X tremendous in presentation AIHA COVID a in X be from about this of Fostamatinib the the This we X its this We we we that very year to a you ago, Amsterdam, use will all COVID would tell during it’s to year, the MIT, more approval of about have patients. capture support in over University XX launched And program. of not as fostamatinib now, has publications substantial you a NIH, very supporting U.S. about
very opportunity addition, tremendous a launched continues In make now own health we’ve address X good crisis. our pipeline progress. to study, to And public lastly, our Phase this
and were convenience to there bit the highlight TNF arthritis, drugs our update, this X details the billions RIP RIPX IBD, pathways. in revenue by program. tremendous multiple RIPX of IRAKX/X these generate will been of are diseases potential of to interest a blocking others. mediated idea and give also Dave We inhibition benefit later with pathways. tremendous. speak currently a and background spondylitis, to ankylosing show take ThX patients attractive our dollars as let or IRAK these over feature. to about either RA, But presentation. inflammatory psoriatic And Lilly the a psoriasis, recently me – call These to RIPX To program. a On that that our Wolfgang I by in potential If Phase the of X, prove two before programs. announced an for has programs; work is pass of include Eli Slide have numerous our minute this treat a There’s the you ThX TNF on it space, more of clinical with may opportunity administration annually indications, oral molecule collaboration very be the on program the in inhibitor little in commercial the
there’s inhibition, addition, opportunity is while broader RIPX a Phase X systemic. with product our In
the variety are We of a exploring Alzheimer’s ALS. molecules including and that cross neurodegenerative diseases, to blood-brain barrier potentially also treat
opportunities, these to Given indicate record of who to program. this came partner we to these to us that thought We was a focus to size major be find diseases ideal of clear on the Lily proven and Lily needed worldwide. the this. and commercializing of it a breadth has for immune developing this a track partner advance top. would
And such an we share them. successes now, discussion, Lily opportunity that CNS and recent as is to as we one both of tremendous In have in necessary these Cymbalta of resources our the has rapidly as then molecules RIPX Lily the and the Zyprexa, inhibitors. in with Alzheimer’s. them, addition, develop tremendous and possible, one commercialize In history discussions appreciation and advances Prozac, pain field; drugs, thing
of makes the All ideal partner this Lilly for program. this
indications, Rigel this million additional for tiered for will address RXXX as the Development and lead to and sales. of very like CNS. autoimmune few milestones, which XXX in royalties in inhibitors costs be from on immune will brain-penetrating and Rigel’s Moving a $XXX aspects to and new unmet both Slide on upfront CNS payment receive all of an medical Lilly for the a between and in highlight Lilly collaboration. net of to on co-develop bring certain Rigel This class indications, potential partner – RIPX Lilly the million up will Rigel and $XXX will clinical to well important Lilly opt-out in a I’d diseases. inhibitor shared has to Rigel. development key RXXX potential needs. subject as focusing future large inflammatory compounds X, provisions commercialize forth RIPX
this commercial with to that, explore excited with like opportunity very for I’d partnership turn Dave? And Dave the are update. a call and We to over Lilly.
